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Abstract
Background: Pertussis diagnosis may go unrecognized when other pathogens, such as respiratory syncytial virus
(RSV) circulate.
Methods: A prospective cross-sectional study was conducted in Lima, Peru from January 2009 to September 2010.
A total of 596 children under 5 years old admitted with clinical diagnoses of acute respiratory infections were test
for B. pertussis and RSV detection by polymerase chain reaction (PCR).
Results: The pertussis toxin and IS481 genes were detected in 19.12 % (114/596) of the cases and the respiratory
syncytial viruses (RSV-A and RSV-B) were identified in 17.28 % (103/596) of patients. Infants under 3 months old
were the most frequently affected by this pathogens in 43 % (49/114) and 35.9 % (37/103) respectively. An increase
of B. pertussis was observed from February to March and from October to November with a Seasonal index
between 1.32 and 1.51 and 1.24–3.5 respectively.
Conclusions: Epidemiologic surveillance for B. pertussis is essential in Peru, especially in children that could most
benefit from the vaccine. B. pertussis should be suspected in infants hospitalized for acute respiratory symptoms for
early treatment and prevent complications.
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Background
Pertussis is an endemic vaccine-preventable disease with
the highest morbidity and mortality in the youngest
infants [1]. Worldwide, there are an estimated of 16 mil-
lion cases of pertussis, 95 % of which occur in develop-
ing countries, resulting in about 195 000 children deaths
per year [1, 2]. In the last years, an increase in reported
cases of pertussis has been noted, even in countries with
high vaccination coverage [3–6].
Bordetella pertussis is a fastidious gram-negative coc-
cobacillus which causes Pertussis disease, a highly conta-
gious infection of the human respiratory tract also
known as “whooping cough” [3, 5]. Pertussis is charac-
terized by three phases: catarrhal, paroxysmal, and con-
valescent; being the most infectious periods the catarrhal
and early paroxysmal phases [7]. This classic presenta-
tion is well-known, but is observed less often since the
start of immunization [4].
The standard diagnostic criteria for B. pertussis identifi-
cation and epidemiological surveillance are culture and
molecular techniques such as polymerase chain reaction
(PCR). The DNA amplification techniques (e.g., PCR) for
B. pertussis detection are faster, and have increase the sen-
sitivity by approximately 19 % the overall percentage of
laboratory-confirmed cases, being the preferred method
[8, 9]. However, in clinical practice the diagnosis is gener-
ally reached without microbiological confirmation leading
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to a possible lack of clinical awareness to start early treat-
ment and prevent complications [10].
Pertussis can be especially difficult to diagnose in chil-
dren under 1 year of age during winter season, when
other pathogens, such as respiratory syncytial virus
(RSV) or Influenza, are prevalent. In these difficult cases,
pertussis acute respiratory symptoms can overlap with
those of bronchiolitis or other unspecific acute respira-
tory infections [10, 11]. This is especially worrisome in
infants too young to be immunized in whom atypical
and more severe presentations have been reported, often
requiring hospitalization for respiratory or other compli-
cations [7, 12, 13].
In Peru, pertussis is a major health problem that has
been raising in the last 5 years [14]. Furthermore, the
most affected are infants under 1 year old representing
38 % of cases, despite a national immunization coverage
of 92 % in this age group [15, 16]. Currently, the “whole
cell” B. pertussis vaccine (DTwP) is the only available
presentation in Peru; and the national coverage level for
this vaccination is 88.3 % for the 3 doses of the pentava-
lent vaccine (DTwP-Hib-HepB) according to the 2014
epidemiology reports [17].
To study the Pertussis epidemiology in Peru is essen-
tial in order to understand the real impact of the disease,
especially in the most vulnerable population. The aim of
this study is to determine the prevalence, epidemio-
logical and clinical characteristics of B. pertussis and
Respiratory syncytial virus cases in infants under 5 years
old hospitalized with acute respiratory infections in a
Peruvian hospital between 2009 and 2010.
Methods
Patients
A prospective cross-sectional study was conducted in
children under 5 years old admitted to “Hospital
Nacional Cayetano Heredia. Lima - Peru” with diag-
nosis of acute respiratory infection (ARI). A total of
596 patients were studied from January 2009 to September
2010. The study region had a representative popula-
tion, since Lima is recognized as B. pertussis endemic
area and has a vaccine coverage similar to the national
reports.
Epidemiological and clinical features were registered,
including: age, gender and clinical symptoms (fever, rhi-
norrhea, cough, respiratory distress, malaise, wheezing,
pharyngeal congestion, expectoration, vomiting, diar-
rhea, among others).
This study was approved by the Research Ethics Board of
the “Hospital Nacional Cayetano Heredia and Universidad
Peruana de Ciencias Aplicadas”. Informed written consent
was given by the parents or legal guardians of the children
before enrolment.
Samples
Two nasopharyngeal samples were obtained per patient.
The first one, by inserting a swab into both nostrils par-
allel to the palate (calcium alginate swab, USA) and a
second swab for the posterior pharyngeal and tonsillar
areas (Viral Culture, Becton-Dickinson Microbiology
Systems, MD, USA). Both nasal and pharyngeal swabs
were placed into the same tube containing viral trans-
port medium (a minimal essential medium buffered with
NaHCO3 and supplemented with 2 % fetal bovine
serum, penicillin and streptomycin 100 U/ml, amphoter-
icin B 20 μg/ml, neomycin 40 μg/ml). The samples were
then stored at 4 °C until being sent to the Laboratory of
molecular biology at “Universidad Peruana de Ciencias
Aplicadas (UPC)”. On receipt of the samples the swabs
were discarded and tubes were centrifuged to pellet the
cells, which were re-suspended in 0.8 ml of PBS 1X.
Two aliquots of 200 μl of each fresh specimen were used
for the extraction of nucleic acids and 200 μl for bacter-
ial culture.
DNA extraction
DNA was extracted from a volume of 200 μl of each
samples using a commercial kit (High Pure Template
Preparation Kit, Roche Applied Science, Germany)
according to the manufacturer´s instructions. DNA ex-
traction was assayed immediately or stored at −80 °C
until use.
PCR amplification
The presence of B. pertussis was determined using two
PCR assays, each specific for an independent region of
the B. pertussis genome. A fragment of 191-bp of the
pertussis toxin S1 gene (PTxA) was amplified using the
primers PTp1: 5´-CCAACGCGCATGCGTGCAGAxT
TCGTC-3´ and PTp2:5´-CCCTCTGCGTTTTGATG
GTGCCTATTTTA- 3´ [18]. Meanwhile a 145 bp frag-
ment of the insertion sequence IS481 was amplified
using the primers IS481F: 5'-GATTCAATAGGTTGTA
TGCATGGTT-3' and IS48R: 5'-TTCAGGCAGACA
AACTTGATGGGCG-3´ [19]. The described procedures
were slightly modified as follows: Fifty μl of reaction
mixture containing 25 ul ready mix enzyme (Taq poli-
merase, 2.5 mM Mg Cl2; 15 mM Tris/HCl PH 8.3,
50 mM KCl, 200 uM each deoxynucleotide) (Kappa Bio-
syste), 20 pmol each primer (Macrogen-Korea), water
and 5 ul DNA were amplified using a pre-denaturation
of 5 min at 95 °C, followed by 55 cycles of denaturation
for 1 min at 95 °C, annealing for 1 min at 55 °C and
elongation for 45 s at 72 °C, with a final elongation of
10 min at 72 °C. The presence and size of amplification
products were analysed by electrophoresis on 2.5 % gel
agarose, containing 3 μg/mL of ethidium bromide, and
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photographed under ultraviolet illumination. The ampli-
fied products were sequenced (Macrogen, Seoul, Korea).
Respiratory syncytial virus (RSV-A and RSV-B) were
identified by multiplex RT-PCR as previously described
by Coiras et. al., [20].
Statistical analysis
Qualitative variables were reported as frequencies and
percentages. All analyses were processed with the IBM
Statistical Package for the Social Sciences (SPSS) software
version 21.0 (SPSS, Chicago, IL, USA). The chi-square test
(χ2-) was used to assess associations between categorical
variables while z-Test was used to 30 is significant. A p-
value <0.05 was considered statistically significant. A sea-
sonal index was calculated for Bordetella and Respiratory
syncytial virus PCR-confirmed cases from January 2009 to
September 2010. Seasonal indexes were calculated divid-
ing the monthly frequency of confirmed cases by the aver-
age of cases per year.
Results
A total of 596 children under 5 years diagnosed with an
acute respiratory infection were admitted to the “Hospital
Nacional Cayetano Heredia. Lima - Peru” from January
2009 to September 2010. The pertussis toxin and IS481
genes were detected in 19.12 % (114/596) of the cases.
Respiratory syncytial viruses (RSV-A and RSV-B) were
identified in 17.28 % (103/596) of patients. Co-infections
between B. pertussis and RSV-A were observed in 14
patients and only one sample was positive for B. pertussis
and RSV-B (Table 1).
Positive samples for B. pertussis and RSV were ana-
lyzed according to age distribution, and infants under
3 months old were the most frequently affected in 43 %
(49/114) and 35.9 % (37/103) respectively. A similar sex
distribution was observed in both groups. Moreover,
around 59 % of enrolled children had a previous contact
with another patient with acute respiratory infections.
An equivalent proportion of household contacts was ob-
served for Bordetella pertussis and RSV positive samples
(Table 1).
A similar clinical symptoms frequency was observed
between patients with B. pertussis and RSV. The most
common symptoms in both groups were fever, cough,
rhinorrhea and respiratory distress, all of them present
in more than 60 % of cases. However, among the
patients with a positive RSV sample a higher rate of Rhi-
norrhea 88.35 %, Respiratory distress 76.70 % and
pharyngeal congestion 33.98 % was observed, in com-
parison with the Pertussis-positive group (Table 2).
Pneumonia was the most frequent clinical diagnosis in
32.38 % (193/596) of the total of patients hospitalized
with acute respiratory infections. The diagnosis of Bron-
chiolitis was more common in children with a positive
sample for RSV in 20.39 % (21/103). On the contrary,
the diagnosis of rhinopharyingitis 6.14 % (7/114) was
more common in patients with positive B. pertussis
(Table 3).
A higher prevalence of B. pertussis cases were registered
between October and November 2009 and February to
April 2010. (Figure 1) Seasonal indexes were calculated
for B. pertussis and RSV positive samples separately. An
increase of pcases was observed from February to March
and from October to November with a Seasonal index
between 1.32 and 1.51 and 1.24–3.5 respectively. A similar
predominance was observed in RSV cases from November
Table 1 General characteristics of Bordetella pertussis and Respiratory Syncytial Virus cases
Characteristic Total ARIa patients Bordetella pertussis RSVb
Frequency (n = 596) Frequency (n = 114) Frequency (n = 103)
N (%) N (%) N (%)
Gender
Female 243 (40.8) 52 (45.6) 46 (44.7)
Male 353 (59.2) 62 (54.4) 57 (55.3)
Age
Newborn (≤28 days) 112 (18.8) 17 (14.9) 11 (10.7)
29 days –≤ 3 months 121(20.3) 32 (28.1) 26 (25.2)
3 – 5 months 82 (13.8) 13 (11.4) 11(10.7)
6 – 11 months 115(19.3) 20 (17.6) 26 (25.2)
1 – 5 years 166 (27.9) 32 (28.1) 29 (28.2)
Contact with another people with ARIa
Yes 353 (59.2) 67 (58.8) 59 (57.3)
Not 243 (40.8) 47 (41.2) 44 (42.7)
ARIa acute respiratory infection
RSVb respiratory syncytial virus
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to December. However, RSV showed to be also frequent
from April to June with a seasonal index between 1.09
and 2.00 (Fig. 2).
Discussion
Bordetella pertussis is a strict human pathogen which
causes whooping cough, an endemic illness responsible
of significant morbidity and mortality, especially in
infants under 6 months old [1, 2, 5]. Although regional
differences exist, Pertussis represents a considerable
global disease burden that has been increasing, even in
countries with high vaccination coverage [2, 5, 13]. In
Peru, an alarming increase of cases has been observed
in the last 5 years, and 56 % of cases are reported in
infants under 1 year old [12, 14–16]. This have raise
especial concern since infants under 6 months old are
more vulnerable to disease related complications and
carry a higher mortality [7, 21, 22].
The most common clinical manifestations of B. pertussis
infections are prolonged and paroxysmal coughing, ac-
companied by inspiratory stridor [1, 3]. However, several
factors are known to affect the disease presentation and
Table 2 Clinical symptoms observed in patients with positive B. pertussis and RSV by PCR
Clinical symptoms Total of patients Patients positive for Bordetella pertussis Patients positive for RSV
Frequency (n = 596) Frequency (n = 114) Frecuency (n = 103)
N (%) N (%) N (%)
Fever 596 (100) 114 (100) 103 (100)
Cough 448 (75.2) 82 (71.9)a 92 (89.32)*
Rinorrhea 448 (75.2) 90 (78.9) 91(88.35)
Respiratory distress 366 (61.4) 69 (60.5)a 79 (76.70)*
Wheezing respiratory 230 (38.6) 40 (35.1)a 59 (57.28)*
Malaise 150 (25.2) 28 (24.6) 24 (23.30)
Pharyngeal congestion 150 (25.2) 25 (21.9)a 35 (33.98)*
Expectoration 142 (23.8) 28 (24.6) 30 (29.13)
Vomits 79 (13.3) 16 (14) 16(15.53)
Diarrhea 71(11.9) 13 (11.4) 15 (14.56)
Asthenia 52 (8.7) 13 (11.4) 9 (8.74)
Conjunctival congestion 23(3.9) 5 (4.4) 5 (4.85)
Abdominal pain 21(3.5) 2 (1.7) 2 (1.94)
Headache 16 (2.7) 3(2.63) 4 (3.88)
Otalgia 6 (1.0) 2 (1.75) 1 (0.97)
Myalgia 6 (1.0) 1(1.75) 1 (0.97)
* z-Test: Patients positive for Bordetella pertussis vs Patients positive for RSV, p < 0.05
Others (<10 % of cases): Ear pain, photophobia, conjunctival congestion, abdominal pain
lymphadenopathy, fatigue, headache, myalgia, skin rash
a3 children died, one of them in the B.pertussis infection group
Table 3 Clinical diagnosis observed in patients with positive B. pertussis and RSV by PCR
Clinical diagnosis Total of patients Patients positive for Bordetella pertussis Patients positive for RSV
Frequency Prevalence Frequency Prevalence p-value** Frequency Prevalence p-value**
(n = 596) (%) (n = 114) (%) (n = 103) (%)
Pneumonia 193 32.38 30 26.32* 0.124 44 42.72* 0.014
Pharyngitis 6 1.01 0 0 0.231 1 0.97 0.968
Rhinopharyngitis 33 5.54 7 6.14 0.754 3 2.91 0.200
Bronchiolitis 57 9.56 9 7.9* 0.327 21 20.39* <0.05
Influenza A Infection 51 8.56 10 8.77 0.927 6 5.83 0.276
Whooping cough-like syndrome 10 1.68 3 2.63 0.378 2 1.94 0.819
Obstruction syndrome to bronchiolar 41 6.88 9 7.89 0.634 11 10.68 0.094
* z-Test: Patients positive for Bordetella pertussis vs Patients positive for RSV, p < 0.05
** χ2-Test
Others (1 % of cases): Sinusitis, respiratory distress syndrome, sepsis late atypical febrile seizure status epilepticus, atypical febrile seizure, gastroenteritis
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Pertussis diagnosis may go unrecognized when other
pathogens, such as respiratory syncytial virus (RSV) or
Influenza virus circulate [10, 23, 24]. A retrospective study
in Italy, from a group of infants hospitalized from October
2008 to April 2010 for acute respiratory symptoms
reported that most of Pertussis cases were infants under
6 months with median of 71.5 days old and a male: female
ratio of 6:13 [10]. In our study pertussis toxin and IS481
genes were detected in 19.12 % (114/596) of the patients
admitted with an acute respiratory infection and infants
under 3 months old were the most frequently affected in
43 % (49/114) with a similar sex distribution.
Co-infection between Bordetella pertussis and RSV
has been previously described to cause severe infections
[10, 11]. A study conducted in a group of infants hospi-
talized for RSV bronchiolitis showed that almost 2 % of
patients were co-infected with B. pertussis [25, 26]. In our
series, co-infections were observed in 14 patients between
B. pertussis and RSV-A and 1 sample was positive for B.
pertussis and RSV-B. Moreover, 6 out of 9 cases of co-
infections were clinically diagnosed as Bronquiolitis and
B. pertussis was not suspected at the time of admission.
Influenza virus and B. pertussis co-infections have been
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with community-acquired pneumonia; and the pertussis
toxin-mediated suppression have been postulate to be re-
sponsible to produce more sever presentations [27, 28].
Multiple studies have reported Paroxysmal cough
(76.5–91.1 %), cyanosis (46.7–81.7 %) and respiratory
distress (47.8–55.7 %) as the most common symptoms
in children [13, 29, 30]. However, several clinical features
might help to suspect the diagnosis of pertussis in
infants hospitalized for acute respiratory symptoms. [10]
One study in 2013, compared infants with Pertussis
and confirmed RSV bronchiolitis; and the clinical char-
acteristics showed that the percentage of infants with
paroxysmal cough was significantly higher in infants
with B. pertussis. Additionally, cough at admission lasted
longer in infants with pertussis than in control infants.
Also, fever was significantly lower in infants with pertus-
sis, and more common in patients with bronchiolitis. In
our study population, a similar clinical symptoms fre-
quency was observed between patients with B. pertussis
and RSV. The most frequently reported symptoms were
fever, cough, rhinorrhea and respiratory distress, in more
than 60 % of cases. However, the presence of rhinorrhea
88.35 %, respiratory distress 76.70 % and pharyngeal
congestion 33.98 % was more common among patients
with RSV. This higher frequency of symptoms in our
study may be related to fact that more than 52 % of our
patients were hospitalized infants under 6 months old.
The clinical diagnosis of Pertussis in infants can be chal-
lenging, especially in children with incomplete immuniza-
tions, and some patients may be catalogued as acute viral
respiratory infections, before laboratory confirmation. Thus
delaying the appropriate antibiotic treatment and isolation
measures [11, 24]. In our series, pneumonia was clearly the
most frequent diagnosis in 26.32 % (30/114) of the patients
with positive B. Pertussis. However, other diagnosis were
considered in this group, such as rhinopharingitis, bron-
chiolitis and influenza infections. In contrast, the diagnosis
of Bronchiolitis was more common in 20.37 % (21/103) of
children with a positive sample for RSV.
For Bordetella pertussis seasonality, a pattern correspond-
ing to the summer and spring months have been reported
in the southern hemisphere [13]. Comparably, a previous
study in infants under 6 month of age from 2003 to 2008 in
Lima, registered more hospitalizations due to whooping
cough during the months of February and September. In
our study, a similar distribution was observed with an
increase of B. pertussis cases from February to March and
from October to November and a Seasonal index between
1.32 and 1.51 and 1.24–3.5 respectively.
Pertussis represents a considerable disease burden in
Peru and the diagnosis is complicated by the limitations of
currently available diagnostic tests. Therefore, the only
diagnostic tests that are recommended for case confirm-
ation in national reporting are culture and polymerase
chain reaction (PCR) [7, 31]. However, in Peru the use
of PCR for surveillance was started recently in 2012
and there is still evidence of a deficient report and
registration of cases that limit the analysis of the real
disease burden.
Conclusions
As in other Latin American countries, epidemiologic
surveillance for B. pertussis is essential in Peru, espe-
cially in children that could most benefit from the vac-
cine. This study demonstrates a considerable incidence
of B. pertussis in children previously diagnosed as acute
respiratory infections and highlights the importance of
possible co-infections that may difficult the diagnosis
and prognosis of patients. There is an increasing need
for further investigations to better establish the impact
of the disease and improve vaccination programs espe-
cially in hospitalized children were more severe presen-
tations have been reported.
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